[
  {
    "ts": null,
    "headline": "Zoetis Inc. stock outperforms competitors on strong trading day",
    "summary": "Zoetis Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=e1e1661df66be8acf8b3cb69fcade2e98ea4240be8bcfb4c443027a3994ddd5b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743093720,
      "headline": "Zoetis Inc. stock outperforms competitors on strong trading day",
      "id": 133491293,
      "image": "",
      "related": "ZTS",
      "source": "MarketWatch",
      "summary": "Zoetis Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=e1e1661df66be8acf8b3cb69fcade2e98ea4240be8bcfb4c443027a3994ddd5b"
    }
  },
  {
    "ts": null,
    "headline": "Kevin O'Leary Paid A Woman On 'Shark Tank' $250K To 'Get Her Out Of Here,' Then Made Millions Off Idea He Called 'Stupid'",
    "summary": "Kevin O'Leary fired off a post on X earlier this month that was part confession, part humblebrag. It started with a cat swab and ended with millions in his pocket. In classic Mr. Wonderful fashion, he admitted he once wrote a $250,000 check—not because he loved the pitch, but because he wanted it to go away. \"A woman pitched me a cat DNA test... for $29,\" he posted. \"I laughed. I told her, ‘I can buy a new cat for five bucks.' But she wouldn't give up. So I wrote a $250K check just to get rid of",
    "url": "https://finnhub.io/api/news?id=fb501d692e9e92ab0734fbc19d59c8f21f93da15a1efe6fff719682c1b35c9c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743084044,
      "headline": "Kevin O'Leary Paid A Woman On 'Shark Tank' $250K To 'Get Her Out Of Here,' Then Made Millions Off Idea He Called 'Stupid'",
      "id": 133481563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Kevin O'Leary fired off a post on X earlier this month that was part confession, part humblebrag. It started with a cat swab and ended with millions in his pocket. In classic Mr. Wonderful fashion, he admitted he once wrote a $250,000 check—not because he loved the pitch, but because he wanted it to go away. \"A woman pitched me a cat DNA test... for $29,\" he posted. \"I laughed. I told her, ‘I can buy a new cat for five bucks.' But she wouldn't give up. So I wrote a $250K check just to get rid of",
      "url": "https://finnhub.io/api/news?id=fb501d692e9e92ab0734fbc19d59c8f21f93da15a1efe6fff719682c1b35c9c8"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy.",
    "summary": "Shares in animal pharmaceutical company Zoetis (NYSE: ZTS) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February.  The Q4 numbers were fine, but the company's revenue guidance fell short of expectations.  One major alternative consideration could end up providing an upside or downside to expectations.",
    "url": "https://finnhub.io/api/news?id=3171ae26e0c0f9f4affe62829dc90f34ae3c27dc4b59f889d7b977b469c8b2d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743082690,
      "headline": "Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy.",
      "id": 133471839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Shares in animal pharmaceutical company Zoetis (NYSE: ZTS) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February.  The Q4 numbers were fine, but the company's revenue guidance fell short of expectations.  One major alternative consideration could end up providing an upside or downside to expectations.",
      "url": "https://finnhub.io/api/news?id=3171ae26e0c0f9f4affe62829dc90f34ae3c27dc4b59f889d7b977b469c8b2d2"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results",
    "summary": "PARSIPPANY, N.J., March 27, 2025--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call.",
    "url": "https://finnhub.io/api/news?id=4b7440deb56aed360e93f4f316ce113b20890b33f4a20041311a179b7be6c4fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743078600,
      "headline": "Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results",
      "id": 133468250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "PARSIPPANY, N.J., March 27, 2025--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call.",
      "url": "https://finnhub.io/api/news?id=4b7440deb56aed360e93f4f316ce113b20890b33f4a20041311a179b7be6c4fd"
    }
  },
  {
    "ts": null,
    "headline": "Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks",
    "summary": "As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.",
    "url": "https://finnhub.io/api/news?id=b1e2f883305349ce1d01625ce242c14b9be2ad36fd1a4464154df6272a622aa2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743066384,
      "headline": "Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks",
      "id": 133468125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.",
      "url": "https://finnhub.io/api/news?id=b1e2f883305349ce1d01625ce242c14b9be2ad36fd1a4464154df6272a622aa2"
    }
  }
]